Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Status:
RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Phase:
PHASE1
Details
Lead Sponsor:
MBX Biosciences